Status:
UNKNOWN
Treatment of Aortic Stenosis in Brazil: Cost-Utility Analysis of TAVI vs SAVR
Lead Sponsor:
Hospital do Coracao
Conditions:
Aortic Stenosis
Eligibility:
All Genders
70+ years
Phase:
NA
Brief Summary
TEAM-Br is a randomized, prospective, cost-utility study comparing transcatheter aortic valve implantation (TAVI) versus surgical aortic vale replacement in Brazil. The study is sponsored by the nati...
Detailed Description
Transcatheter aortic valve implantation has been shown to be non-inferior to surgical aortic valve replacement in patients with severe aortic stenosis at high, intermediate and low surgical risk. In r...
Eligibility Criteria
Inclusion
- Age \> 70 years;
- Symptoms of heart failure NYHA class \> II;
- Severe aortic stenosis (as defined by echocardiography: mean gradient \>40 mmHg or jet velocity greater than 4.0 m/s or an initial aortic valve area of \< 1.0 cm2)
- Heart team (including examining cardiac surgeon) agree on eligibility including assessment that TAVR or SAVR is appropriate;
- The study patient or the study patient's legal representative informed of the nature of the study, agreed to its provisions and provided written informed consent as approved by the Institutional Review Board (IRB) center;
- The study patient agreed to comply with all required post-procedure follow-up visits including visits through 1 month and 1 year;
- Heart team agreed (a priori) on treatment strategy for concomitant coronary disease (if present);
- Patient agreed to undergo surgical aortic valve replacement (SAVR) if randomized to control treatment.
Exclusion
- Heart Team assessment of inoperability (including examining cardiac surgeon);
- Hostile chest
- Evidence of an acute myocardial infarction ≤ 1 month (30 days) before the intended treatment \[defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB ≥ twice normal in the presence of MB elevation and/or troponin level elevation (WHO definition)\];
- Concomitant severe valvular disease (mitral, tricuspid or pulmonic) requiring surgical intervention;
- Preexisting mechanical or bioprosthetic aortic valve with dysfunction;
- Complex coronary artery disease: unprotected left main coronary artery, Syntax score \> 32 (in the absence of prior revascularization);
- Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days of the index procedure (unless part of planned strategy for treatment of concomitant coronary artery disease). Implantation of a permanent pacemaker is not an exclusion criteria;
- Leukopenia (WBC \< 3000 cell/mL), acute anemia (Hgb \< 9 g/dL), thrombocytopenia (Plt \< 50,000 cell/mL);
- Hypertrophic cardiomyopathy with or without obstruction (HOCM);
- Severe ventricular dysfunction with LVEF \< 20%;
- Echocardiographic evidence of intracardiac mass, thrombus or vegetation;
- Active upper GI bleeding within 3 months (90 days) prior to procedure;
- A known contraindication or hypersensitivity to all anticoagulation regimens, or inability to be anticoagulated for the study procedure;
- Clinically (by neurologist) or neuroimaging confirmed stroke or transient ischemic attack (TIA) within 6 months (180 days) of the procedure;
- Renal insufficiency (creatinine \> 3.0 mg/dL) and/or renal replacement therapy at the time of screening;
- Estimated life expectancy \< 24 months (730 days) due to carcinomas, chronic liver disease, chronic renal disease or chronic end stage pulmonary disease;
- Currently participating in an investigational drug or another device study;
- Active bacterial endocarditis within 6 months (180 days) of procedure;
- Patient refuses surgery for aortic valve replacement.
Key Trial Info
Start Date :
December 10 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT04067089
Start Date
December 10 2018
End Date
December 31 2023
Last Update
March 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital do Coracao
São Paulo, São Paulo, Brazil, 04005-000